Data from the IMPRESS study 2,3
AIM: To compare resource use in the 6 and 12 months before and after rifaximin-α initiation in UK patients with HE.
This study was sponsored by Norgine.
Details of hospitalisations and hospital visits were extracted from NHS Trust electronic databases. Analysis included only alive patients at the end of 6 and 12 month periods. IMPRESS study was sponsored and funded by Norgine
Rifaximin-α initiation dose was 1100mg/day (licensed dose) in 30%, 1200 mg/day in 64%, and other doses in 6% of patients, respectively. This study included patients started on rifaximin-a prior to the launch of TARGAXAN® 550mg bd. 82% of patients (n=119) were taking concomitant lactulose at baseline.